BSE NSE
Your Result on : Detailed News
Back
Natco Pharma signs pact with Eli Lilly for COVID drug in India
17-May-21   15:19 Hrs IST

In line with the licensing agreement, Natco Pharma has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for COVID-19 in India.

Natco Pharma had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

The drug maker's consolidated net profit dropped 39.3% to Rs 63.40 crore on 26.3% fall in net sales at Rs 355.20 crore in Q3 FY21 over Q3 FY20.

Natco Pharma manufactures a comprehensive range of branded and generic dosage forms, bulk actives and intermediates for both Indian as well as International markets.

Shares of Natco Pharma lost 0.94% to Rs 919.60 on BSE. The scrip hovered in the range of Rs 918 to Rs 945 so far.

Powered by Capital Market - Live News

Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
GANESH S SHANBHAG--NSE SEBI No. AP1413003821 | BSE SEBI No. AP0109180198601
2017-18 © SMS Financial Services. All rights reserved. Designed, developed & powered by C-MOTS Infotech (ISO 9001:2015 certified)